Rationale and design of a multicenter study of selegiline and α-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes

Alzheimer Disease and Associated Disorders

Volumn 10, Issue 3, 1996, Pages 132-140

  Sano, Mary ^a,e   Ernesto, Christopher ^b   Klauber, Melville R ^b   Schafer, Kimberly ^b   Woodbury, Peter ^b   Thomas, Ronald ^b   Grundman, Michael ^b,c   Growdon, John ^d   Thal, Leon J ^b,c  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Department of Orthopaedic Surgery   (United States)

Author keywords

Alzheimer disease; Selegine; Tocopherol clinical trial

Indexed keywords

ALPHA TOCOPHEROL; MONOAMINE OXIDASE INHIBITOR; SELEGILINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEATH; DEMENTIA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INSTITUTIONALIZATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME;

EID: 9544258368     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199601030-00004     Document Type: Article

References (41)

1. Anderson DK, Waters TR, Means ED. Pretreatment with alpha tocopherol enhances neurologic recovery after experimental spinal compression injury. J Neurotrauma 1988;5:61-7.
2. Behl C, Davis J, Cole G, Shubert D. Vitamin E protects nerve cells from beta-amyloid protein toxicity. Biochem Biophys Res Commun 1992;186:944-50.
3. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and senile changes in the cerebral grey matter of elderly patients. Br J Psychiaity 1968;114:797-811.
4. Bondareff W, Mountjoy CQ, Roth M. Selective loss of neurons of origin of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Lancet 1981;l:783-4.
5. Braak H, Braak E. Pathology of Alzheimer's disease. In: Calne D, ed. Neurodegenerative diseases. Philadelphia: Saunders, 1994;585-614.
6. Burke WJ, Miller JP, Rubin EH, et al. The reliability of the Washington University Clinical Dementia Rating. Arch Neurol 1988;45:31-2.
7. Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK. L-Deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993;41:1219-25.
8. Davis P. An update on the neurochemistry of Alzheimer disease. In: Mayeux R, Rosen WG, eds. The dementias. New York: Raven Press, 1983:75-86.
9. Davis PB, White H, Price JL, McKeel D, Robins LN. Retrospective postmortem dementia assessment. Validation of a new clinical interview to assist neuropathologic studies. Arch Neurol 1991;48:613-7.
10. Dawes RM, Faust D, Meehl PE. Clinical versus actuarial judgement. Science 1989;243:1668-73.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
12. Halliwell B, Gutteridge JMC. Oxygen radicals in the nervous system. Trends Neurosci 1985;8:22-6.
13. Hara H, Kato H, Kogure K. Protective effect of alpha-tocopherol on ischemic neuronal damage in the gerbil hippocampus. Brain Res 1990;510:335-8.
14. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. TIPS 1992;121:383-8.
15. Harman D. The free radical theory of aging. In: Pryor WA, ed. Free radicals in biology. New York: Academic Press, 1982:255-75.
16. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 1983;95:57-80.
17. Laird NM, Ware JH. Random effects models for longitudinal data. Bio- metrics 1982;38:963-74.
18. Levine RL, Oliver CN, Fulks RM, Stadtman ER. Turnover of bacterial glutamine synthetase: oxidative inactivation precedes proteolysis. Proc Natl Acad Sci USA 1981;78:2121-4.
19. Mair RG, McEntee WJ. Cognitive enhancement in Korsakoff's psychosis by clonidine: a comparison with L-dopa and ephedrine. Psychopharmacology 1986;88:274-80.
20. Mangoni A, Grassi MP, Frattola L, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer's disease. Eur Neurol 1991;31:100-7.
21. McCulla MM, Coates M, Van Fleet N, Duchek J, Grant E, Morris JC. Reliability of clinical nurse specialists in the staging of dementia. Arch Neurol 1989;46:1210-1.
22. McEntee WJ, Mair RG, Langlais PJ. Neurochemical pathology in Korsakoff's psychosis: implications for other cognitive disorders. Neurology 1984;34:648-52.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of HHS Task Force on Alzheimer's Disease. Neurology 1984;34:939-45.
24. Miller RG. What price Kaplan-Meier? Biometrics 1983;39:1077-81.
25. Mirra S, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology 1991;41:479-86.
26. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-71.
27. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83.
28. Physicians 'desk reference. 49th ed. Montvale: Medical Economics Production, 1995:1826-31.
29. Piccinin GL, Finali G, Piccirilli M. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol 1990; 13:147-63.
30. Porta EA. Role of oxidative damage in the aging process. In: Chow CK, ed. Cellular antioxidant defense mechanisms, vol. 3. Boca Raton: CRC Press, 1988:2-52.
31. Richards M, Marder K, Bell K, Dooneief G, Mayeux R, Stern Y. Interrater reliability of extrapyramidal signs in a group assessed for dementia. Arch Neurol 1991;48:1147-9.
32. Rocca WA, Hofman A, Brayne C, et al. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. Ann Neurol 1991;30:381-90.
33. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
34. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathologic verification of ischemic score in differentiation of dementia. Ann Neurol 1980;7:486-88.
35. Sano M, Morris J, Thai E, et al. Developing outcome measures for clinical trials by the Alzheimer's Disease Cooperative Study (ADCS): standardized training for the Clinical Dementia Rating (CDR), initial results. Neurology 1993;43:A291-2.
36. Smith CD, Carney JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer's disease. Proc Natl Acad Sci USA 1991;88:10540-3.
37. Stern Y, Albert S, Sano M, et al. Assessing dependence in Alzheimer's disease. J Gerontol A Biol Sci Med Sci 1994;49:M216-22.
38. Stern Y, Mayeux R, Sano M, Hauser WA, Bush T. Predictors of disease course in patients with probable Alzheimer's disease. Neurology 1987;37:1649-53.
39. Tariot PN, Mack JE, Patterson MB, et al. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry 1995; 152:1349-57.
40. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245:519-22.
41. Zeger SE, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44:1049-60.